Renal Carcinoma Clinical Trial
Official title:
Robot-Assisted Laparoscopic HIFU (High-Intensity Focused Ultrasound) for Thermal Ablative Therapy of Small Renal Mass: Corroborating With Robot-Assisted Laparoscopic Partial Nephrectomy Specimens
Verified date | December 2017 |
Source | University of Southern California |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This clinical trial studies a type of ultrasound called robot-assisted laparoscopic high-intensity focused ultrasound for performing thermal ablative therapy, or sound wave therapy, in treating patients with small kidney masses undergoing partial removal of the kidney. The robot-assisted ultrasound probe takes images of the kidney to help doctors locate the mass. The probe then uses high frequency sound waves to target and ablate (or destroy) the kidney mass, which may be a cancerous tumor or benign tissue. Surgery is then performed to remove the part of the kidney with the mass. Robot-assisted laparoscopic high-intensity focused ultrasound for thermal ablative therapy may be safer and help doctors see the tumor better when performing kidney surgery.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | December 18, 2019 |
Est. primary completion date | December 18, 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Presence of an enhancing solid renal mass =< 3.0 cm on radiological examination - Tumors with a depth of not greater than 3.0 cm from a laparoscopically accessible surface-meaning no part of the tumor should be deeper than 3.0 cm from the surface - Patients with solitary kidneys, bilateral renal tumors, compromised renal function (baseline creatinine > 1.4) - Subjects must have given written informed consent - Previous chemotherapy, and/or biological therapy for cancer are permitted provided that the acoustic properties of the tumor were not affected, but the subject should have recovered from the effects of these or of any prior surgery - Subjects must be free of any clinically significant disease other than cancer that would interfere with the study evaluations - Absolute neutrophil count (ANC) >= 1500 mm^-3 - Platelet count >= 100,000 mm^-3 - Hemoglobin >= 10 g/dl - Prothrombin time (PT) =< 1.5 times upper limit of laboratory normal (ULN) - Activated partial thromboplastin time =< 1.5 times ULN - Urea and serum creatinine < 2.5 times ULN - Total bilirubin < 1.5 times ULN - Aspartate aminotransferase (AST) =< 3 times ULN - Alkaline phosphatase < 2 times ULN, unless arising from bone Exclusion Criteria: - < 90% solid component on screening cross-sectional imaging - Subjects deemed unsuitable candidates and not medically optimized for partial nephrectomy - Tumors greater than 3.0 cm at their widest point - Subjects with tumors lying < 1 cm from sensitive structures such as the ureter, renal vessels or adjacent bowel - Subjects on concurrent anticoagulant, or immunosuppressive medication - Subjects on anti-cancer medication whether biologic or pharmaceutical - Women who are pregnant or nursing (pregnancy test to be performed within 24 hours prior to HIFU treatment) - Subjects assessed by consultant anesthetist as unsuitable for general anesthetic - Subjects having had prior ablation therapy on the same tumor |
Country | Name | City | State |
---|---|---|---|
United States | Keck Hospital of USC | Los Angeles | California |
United States | USC Norris Comprehensive Cancer Center | Los Angeles | California |
Lead Sponsor | Collaborator |
---|---|
University of Southern California | National Cancer Institute (NCI) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Planned ablation volume | Ablation area of the kidney mass will be compared to the planned area under histopathologic review. Analyzed using a one-sided one sample T-test. | Baseline (day of surgery) | |
Primary | Necrosis volume | Ablation area of the kidney mass will be compared to the planned area under histopathologic review. Analyzed using a one-sided one sample T-test. | Baseline (day of surgery) | |
Secondary | Tumor response | Up to 4 years | ||
Secondary | Disease free interval | From the date of treatment to the date of local or distant failure or until date of death, assessed up to 4 years | ||
Secondary | Time to local failure | From the date of treatment to the time to local failure, assessed up to 4 years | ||
Secondary | Time to distant failure | From the date of treatment to the time to documented metastatic disease, assessed up to 4 years | ||
Secondary | Overall success rate, measured as the combination of achieving local control of kidney cancer and demonstration of a favorable safety profile evidenced by enumeration of all adverse events by type, severity, and frequency | Up to 4 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04718584 -
the Efficacy and Safety of LDP in Patients With Urinary and Male Genital Tumors
|
Phase 2 | |
Recruiting |
NCT03114826 -
Study of the Impact of VEGF Polymorphism on the Development of Renal Carcinoma in Renal Transplant Patients
|
N/A | |
Recruiting |
NCT02928692 -
Minocycline Attenuate Postoperative Cognitive Dysfunction and Delirium
|
Phase 3 | |
Recruiting |
NCT03475953 -
A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT03638206 -
Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
|
Phase 1/Phase 2 | |
Recruiting |
NCT03786796 -
Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations
|
Phase 2 | |
Completed |
NCT03064308 -
The Assessment of the Feasibility of a Home Based Exercise Programme in the Older Patient Following Major Surgery
|
N/A | |
Not yet recruiting |
NCT06318871 -
Memory-like Natural Killer (NK) Cell Therapy With N-803 in Patients With Renal Cell Carcinoma or Urothelial Carcinoma
|
Early Phase 1 | |
Not yet recruiting |
NCT05456074 -
Integrative Molecular Characterization Of MiT Family Translocation Renal Cell Carcinomas (IMCOR)
|
||
Recruiting |
NCT06290427 -
Comparison of Outcomes of Multiple Platforms for Assisted Robotic-Kidney (COMPAR-K)
|
N/A | |
Recruiting |
NCT04773951 -
A Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics of JS004 in Advanced Solid Tumors
|
Phase 1 |